PRA Health Sciences (NASDAQ:PRAH) had a weak trading session and its shares were last down at $45.13, down -0.1% or -0.22 points. The trading data also revealed that the total net flow stood at $0.78 million as the shares had $2.17 million in upticks but lost $1.39 million in downticks. The up/down ratio was 1.56. This data is particularly important for the traders and speculators alike as it could also be used to gauge the strength of the momentum in the shares. During the past week, the shares have seen a change of -4.77% in the shares.The block trade data suggests an inflow of $0.49 million in upticks and an outflow of $0 million in downticks. The up/down ratio for the block stood at 0. The net money flow for this transaction was recorded at $0.49.
Currently the company Insiders own 2.5% of PRA Health Sciences shares according to the proxy statements. On the companys insider trading activities,The officer (Executive VP & CFO) of Pra Health Sciences, Inc., Baddour Linda sold 92,308 shares at $46.7 on May 6, 2016. The Insider selling transaction had a total value worth of $4,310,784. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
PRA Health Sciences (NASDAQ:PRAH) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.34 points or 0.75% at $44.89 with 515,682 shares getting traded. Post opening the session at $46.47, the shares hit an intraday low of $44.53 and an intraday high of $46.47 and the price was in this range throughout the day. The company has a market cap of $2,718 million and the number of outstanding shares have been calculated to be 60,555,119 shares. The 52-week high of PRA Health Sciences (NASDAQ:PRAH) is $51.35 and the 52-week low is $33.
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Citigroup upgrades its rating on PRA Health Sciences (NASDAQ:PRAH). The rating major has initiated the coverage with buy rating on the shares. Earlier, the shares were rated a Neutral by the brokerage firm. The Analysts at Citigroup raises the price target from $51 per share to $53 per share. The rating by the firm was issued on May 4, 2016.
PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs, from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.